Hello
As stakeholders are now starting to implement the Canadian clinical Drug Data Set (CCDD), we are getting implementation related questions that we would like to discuss with this community.
We previously discussed the Manufactured product granularity issue (please find the discussion document here -
infocentral.infoway-inforoute.ca/en/resources/docs/med-mgmt/canadian-clinical-drug-data-set/ccdd-discussion-papers/2133-issue-paper-12-manufactured-product-and-din-granularity
We proceeded to add more granular content to the CCDD as in the Diastat example below:
There is one DIN to represent the following different products in use which have been encoded and added to the CCDD Manufactured Product file
DIASTAT (diazepam 2.5 mg per 0.5 mL rectal gel tube) VALEANT PHARMACEUTICALS NORTH AMERICA LLC
DIASTAT (diazepam 5 mg per 1 mL rectal gel tube) VALEANT PHARMACEUTICALS NORTH AMERICA LLC
DIASTAT (diazepam 7.5 mg per 1.5 mL rectal gel tube) VALEANT PHARMACEUTICALS NORTH AMERICA LLC
DIASTAT (diazepam 15 mg per 3 mL rectal gel tube) VALEANT PHARMACEUTICALS NORTH AMERICA LLC
DIASTAT (diazepam 20 mg per 4 mL rectal gel tube) VALEANT PHARMACEUTICALS NORTH AMERICA LLC
The question that arises is how should a jurisdictional Drug Information system or other systems implement the above example if they currently only use the higher level DIN which is “DIASTAT (diazepam 5 mg per 1 mL rectal gel tube) VALEANT PHARMACEUTICALS NORTH AMERICA LLC”?
I will be scheduling a call for noon Dec 4th to discuss this question. I look forward to collaboration on the best way forward. I will share an options paper as soon as possible.
thankyou Beverly